Raf kinase inhibitory protein role in the molecular subtyping of breast cancer

Journal of Cellular Biochemistry

Volumn 115, Issue 3, 2014, Pages 488-497

  Al Mulla, Fahd ^a   Marafie, Makia ^b   Tan, Tuan Zea ^c   Thiery, Jean Paul ^c,d,e  

^a KUWAIT UNIVERSITY   (Kuwait)

^b AL SABAH HOSPITAL   (Kuwait)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

AGGRESSIVE CANCER; BASAL; BREAST CANCER; CLAUDIN LOW; DISEASE FREE SURVIVAL; ERBB2; ERK; ESTROGEN RECEPTOR; LUMINAL A; PEBP1; PROGNOSIS; RKIP

Indexed keywords

CLAUDIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN;

ADULT; ARTICLE; BASAL LIKE BREAST CANCER; BREAST CANCER; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER SURVIVOR; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MOLECULAR TYPING; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL;

AGGRESSIVE CANCER; BASAL; BREAST CANCER; CLAUDIN-LOW; DISEASE-FREE SURVIVAL; ERBB2; ERK; ESTROGEN RECEPTOR; LUMINAL A; PEBP1; PROGNOSIS; RKIP;

BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROGNOSIS; RECEPTOR, ERBB-2;

EID: 84892724634     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24682     Document Type: Article

References (35)

1. Al-Mulla F,. 2012. RKIP and cellular motility. J Cell Physiol 227: 2969-2970.
2. Al-Mulla F, Bitar MS, Al-Maghrebi M, Behbehani AI, Al-Ali W, Rath O, Doyle B, Tan KY, Pitt A, Kolch W,. 2011a. Raf kinase inhibitor protein RKIP enhances signaling by glycogen synthase kinase-3beta. Cancer Res 71: 1334-1343.
3. Al-Mulla F, Bitar MS, Taqi Z, Rath O, Kolch W,. 2011b. RAF kinase inhibitory protein (RKIP) modulates cell cycle kinetics and motility. Mol Biosyst 7: 928-941.
4. Al-Mulla F, Bitar MS, Feng J, Park S, Yeung KC,. 2012. A new model for Raf kinase inhibitory protein induced chemotherapeutic resistance. PLoS ONE 7: e29532.
5. Al-Mulla F, Bitar MS, Taqi Z, Yeung KC,. 2013. RKIP: Much more than Raf kinase inhibitory protein. J Cell Physiol 228: 1688-1702.
6. Aranovich A, Liu Q, Collins T, Geng F, Dixit S, Leber B, Andrews DW,. 2012. Differences in the mechanisms of proapoptotic BH3 proteins binding to Bcl-XL and Bcl-2 quantified in live MCF-7 cells. Mol Cell 45: 754-763.
7. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM,. 2007. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13: 2329-2334.
8. da Huang W, Sherman BT, Lempicki RA,. 2009. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
9. Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, Mariani G, Rodriguez J, Carcangiu M, Watson D, Valagussa P, Rouzier R, Symmans WF, Ross JS, Hortobagyi GN, Pusztai L, Shak S,. 2005. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23: 7265-7277.
10. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ,. 2011. Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22: 1736-1747.
11. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gomez HL, Hortobagyi GN, Pusztai L,. 2006. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24: 4236-4244.
12. Huang Y, Liu D, Chen B, Zeng J, Wang L, Zhang S, Mo X, Li W,. 2012. Loss of bad expression confers poor prognosis in non-small cell lung cancer. Med Oncol 29: 1648-1655.
13. Johnson WE, Li C, Rabinovic A,. 2007. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8: 118-127.
14. Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, Gillet C, Ellis P, Ryder K, Reid JF, Daidone MG, Pierotti MA, Berns EM, Jansen MP, Foekens JA, Delorenzi M, Bontempi G, Piccart MJ, Sotiriou C,. 2008. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 9: 239.
15. McShane LM, Altman DG, Sauerbrei W,. 2005. Identification of clinically useful cancer prognostic factors: What are we missing ? J Natl Cancer Inst 97: 1023-1025.
16. Mukherjee D, Zhao J,. 2013. The role of chemokine receptor CXCR4 in breast cancer metastasis. Am J Cancer Res 3: 46-57.
17. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A,. 2001. Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50-56.
18. Muller A, Sonkoly E, Eulert C, Gerber PA, Kubitza R, Schirlau K, Franken-Kunkel P, Poremba C, Snyderman C, Klotz LO, Ruzicka T, Bier H, Zlotnik A, Whiteside TL, Homey B, Hoffmann TK,. 2006. Chemokine receptors in head and neck cancer: Association with metastatic spread and regulation during chemotherapy. Int J Cancer 118: 2147-2157.
19. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N,. 2004. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826.
20. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE, Jr., Wickerham DL, Wolmark N,. 2006. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24: 3726-3734.
21. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS,. 2009. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27: 1160-1167.
22. Perou CM,. 2010. Molecular stratification of triple-negative breast cancers. Oncologist 15 (Suppl 5): 39-48.
23. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D,. 2000. Molecular portraits of human breast tumours. Nature 406: 747-752.
24. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM,. 2010. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12: R68.
25. Prat A, Parker JS, Fan C, Cheang MC, Miller LD, Bergh J, Chia SK, Bernard PS, Nielsen TO, Ellis MJ, Carey LA, Perou CM,. 2012a. Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Ann Oncol 23: 2866-2873.
26. Prat A, Parker JS, Fan C, Perou CM,. 2012b. PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer. Breast Cancer Res Treat 135: 301-306.
27. Prat A, Cheang MC, Martin M, Parker JS, Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen TO, Perou CM,. 2013. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol 31: 203-209.
28. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL,. 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874.
29. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M,. 2006. Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98: 262-272.
30. Straver ME, Glas AM, Hannemann J, Wesseling J, van de Vijver MJ, Rutgers EJ, Vrancken Peeters MJ, van Tinteren H, van't Veer LJ, Rodenhuis S,. 2010. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 119: 551-558.
31. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH,. 2002. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536.
32. Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, Fereday S, Lawrence M, Carter SL, Mermel CH, Kostic AD, Etemadmoghadam D, Saksena G, Cibulskis K, Duraisamy S, Levanon K, Sougnez C, Tsherniak A, Gomez S, Onofrio R, Gabriel S, Chin L, Zhang N, Spellman PT, Zhang Y, Akbani R, Hoadley KA, Kahn A, Kobel M, Huntsman D, Soslow RA, Defazio A, Birrer MJ, Gray JW, Weinstein JN, Bowtell DD, Drapkin R, Mesirov JP, Getz G, Levine DA, Meyerson M,. 2013. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest 123: 517-525.
33. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H,. 2010. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28: 1684-1691.
34. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA,. 2005. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671-679.
35. Zhang D, Tai LK, Wong LL, Putti TC, Sethi SK, Teh M, Koay ES,. 2008. Proteomic characterization of differentially expressed proteins in breast cancer: Expression of hnRNP H1, RKIP and GRP78 is strongly associated with HER-2/neu status. Proteomics Clin Appl 2: 99-107.